Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Regeneron Schedules December 20, 2010 Teleconference and Webcast to Discuss Results of VEGF Trap-Eye Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and Phase 2 Study i…

December 19, 2010 By Bio-Medicine.Org

TARRYTOWN, N.Y., Dec. 20, 2010 /PRNewswire-FirstCall/ —
Regeneron Pharmaceuticals, Inc. (Nasdaq:
REGN
) today announced that it will hold a teleconference and
webcast at 8:30 a.m. Eastern Time on Monday, December 20, to
discuss results of the Phase 3 COPERNICUS study with VEGF Trap-Eye
in central retinal vein occlusion (CRVO) and the week 52 follow-up
results of the Phase 2 DA VINCI study in patients with diabetic
macular edema (DME).  A press release will be issued prior to
the call.

Teleconference/Webcast Details To participate in the live
call on Monday, December 20, at 8:30 a.m. Eastern Time, please dial
(877) 390-5538 for domestic callers and (408) 940-3843 for
international callers, participant code 33105543.  The live
conference call is being webcast and it can be accessed on the
“Newsroom” page of the Company’s web site, www.regeneron.com.  The
webcast will be available for 30 days following the call.About
Regeneron PharmaceuticalsRegeneron is a fully integrated
biopharmaceutical company that discovers, develops, and
commercializes medicines for the treatment of serious medical
conditions.  In addition to ARCALYST® (rilonacept)
Injection for Subcutaneous Use, its first commercialized product,
Regeneron has therapeutic candidates in Phase 3 clinical trials for
the potential treatment of gout, diseases of the eye (wet
age-related macular degeneration and central retinal vein
occlusion), and certain cancers.  Additional therapeutic
candidates developed from proprietary Regeneron technologies for
creating fully human monoclonal antibodies are in earlier stage
development programs in rheumatoid arthritis and other inflammatory
conditions, pain, cholesterol reduction, allergic and immune
conditions, and cancer.  Additional information about
Regeneron and recent news releases are available on Regen

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech